[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
[ Wed, Jan 04th 2023 ]: WOPRAI
Douglas Miehm Maintained (AUPH) at Buy with Increased Target to $11 on, Jan 4th, 2023
- 🞛 This publication is a summary or evaluation of another publication
Douglas Miehm of RBC Capital, Maintained "Aurinia Pharmaceuticals Inc." (AUPH) at Buy with Increased Target from $10 to $11 on, Jan 4th, 2023.
Douglas has made no other calls on AUPH in the last 4 months.
There are 3 other peers that have a rating on AUPH. Out of the 3 peers that are also analyzing AUPH, 1 agrees with Douglas's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Justin Kim of "Oppenheimer" Downgraded from Buy to Hold on, Friday, November 4th, 2022
These are the ratings of the 2 analyists that currently disagree with Douglas
- Ed Arce of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $14 on, Monday, November 7th, 2022
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Decreased Target to $12 on, Friday, November 4th, 2022